Kumovis
Founded Year
2017Stage
Acquired | AcquiredTotal Raised
$3.97MAbout Kumovis
Kumovis creates three-dimensional (3D) printing technology for industrial and medical purposes. The company specializes in the production of high-performance polymers and patient-specific implants, allowing hospitals to undertake medical surgeries and treatments in an effective manner. It was founded in 2017 and is based in Munich, Germany. In February 2022, Kumovis was acquired by 3D Systems.
Loading...
Loading...
Kumovis Patents
Kumovis has filed 5 patents.
The 3 most popular patent topics include:
- 3d printing
- fused filament fabrication
- manufacturing
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/18/2020 | 4/18/2023 | Fused filament fabrication, Manufacturing, 3D printing, 3D printing processes, Production and manufacturing | Grant |
Application Date | 8/18/2020 |
|---|---|
Grant Date | 4/18/2023 |
Title | |
Related Topics | Fused filament fabrication, Manufacturing, 3D printing, 3D printing processes, Production and manufacturing |
Status | Grant |
Latest Kumovis News
Apr 21, 2023
Austria´s Salzburg University Hospital has 3D printed a polyether ether ketone (PEEK) cranial implant in-house and implanted it into a 55-year-old man suffering from a skull deformity. Although PEEK has... The post Hospital 3D Prints and Implants Skull Device In-House Using Kumovis Material Extrusion appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.
Kumovis Frequently Asked Questions (FAQ)
When was Kumovis founded?
Kumovis was founded in 2017.
Where is Kumovis's headquarters?
Kumovis's headquarters is located at Trimburgstrasse 2, Munich.
What is Kumovis's latest funding round?
Kumovis's latest funding round is Acquired.
How much did Kumovis raise?
Kumovis raised a total of $3.97M.
Who are the investors of Kumovis?
Investors of Kumovis include 3D Systems, German Accelerator Life Sciences Program, High-Tech Grunderfonds, Renolit, Solvay Ventures and 4 more.
Loading...
Loading...